NCT06526923View on ClinicalTrials.gov

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cystic Fibrosis
Interventions
COMBINATION_PRODUCT

SP-101 and doxorubicin Cohort 1

Single inhaled dose of SP-101 and doxorubicin Dose 1

COMBINATION_PRODUCT

SP-101 and doxorubicin Cohort 2

Single inhaled dose of SP-101 and doxorubicin Dose 2

Trial Locations (4)

10032

RECRUITING

Columbia University, New York

19104

RECRUITING

Hospital at University of Pennsylvania, Philadelphia

66160

RECRUITING

University of Kansas Medical Center, Kansas City

02115

RECRUITING

Boston Children's Hospital, Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Spirovant Sciences, Inc.

INDUSTRY